COMPASS Pathways (NASDAQ:CMPS) Trading Down 7.6% – Here’s Why

Shares of COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) were down 7.6% during trading on Monday . The stock traded as low as $6.65 and last traded at $6.6250. Approximately 400,694 shares were traded during trading, a decline of 73% from the average daily volume of 1,507,353 shares. The stock had previously closed at $7.17.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CMPS shares. Morgan Stanley increased their price target on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday, January 21st. BTIG Research boosted their price target on COMPASS Pathways from $7.00 to $14.00 and gave the stock a “buy” rating in a research note on Monday, October 13th. Finally, Royal Bank Of Canada upped their price target on COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $16.25.

COMPASS Pathways Stock Down 4.0%

The firm has a 50 day moving average price of $6.48 and a 200 day moving average price of $5.66. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. Sell-side analysts expect that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

Institutional Trading of COMPASS Pathways

Several institutional investors have recently made changes to their positions in CMPS. U.S. Capital Wealth Advisors LLC purchased a new position in COMPASS Pathways in the 4th quarter worth approximately $104,000. Hennion & Walsh Asset Management Inc. boosted its position in shares of COMPASS Pathways by 169.0% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 424,800 shares of the company’s stock worth $2,931,000 after acquiring an additional 266,908 shares during the last quarter. Advisory Services Network LLC purchased a new position in COMPASS Pathways during the third quarter valued at $41,000. Parkman Healthcare Partners LLC bought a new stake in COMPASS Pathways in the 3rd quarter valued at $573,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in COMPASS Pathways in the 3rd quarter worth $118,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.